$SILK
Silk Road Medical Inc

2021 Q4 Form 10-Q Financial Statement

#000139770221000063 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $28.27M $24.70M $20.07M
YoY Change 33.75% 23.09% 17.86%
Cost Of Revenue $7.233M $6.076M $5.488M
YoY Change 38.56% 10.71% 31.61%
Gross Profit $21.03M $18.63M $14.58M
YoY Change 32.14% 27.75% 13.4%
Gross Profit Margin 74.41% 75.4% 72.65%
Selling, General & Admin $27.60M $25.05M $19.20M
YoY Change 32.22% 30.45% 12.53%
% of Gross Profit 131.2% 134.49% 131.71%
Research & Development $7.499M $6.867M $4.711M
YoY Change -25.31% 45.77% 47.82%
% of Gross Profit 35.66% 36.87% 32.31%
Depreciation & Amortization $309.0K $241.0K $190.0K
YoY Change 34.35% 26.84% 5.56%
% of Gross Profit 1.47% 1.29% 1.3%
Operating Expenses $35.09M $31.92M $23.91M
YoY Change 13.54% 33.47% 18.08%
Operating Profit -$14.06M -$13.29M -$9.334M
YoY Change -6.22% 42.39% 26.22%
Interest Expense -$619.0K $633.0K $1.215M
YoY Change -3.28% -47.9% 3.32%
% of Operating Profit
Other Income/Expense, Net -$12.00K -$3.000K -$15.00K
YoY Change 20.0% -80.0% 1400.0%
Pretax Income -$14.69M -$13.89M -$10.32M
YoY Change -12.33% 34.54% 28.84%
Income Tax
% Of Pretax Income
Net Earnings -$14.69M -$13.89M -$10.32M
YoY Change -12.31% 34.61% 28.82%
Net Earnings / Revenue -51.98% -56.21% -51.4%
Basic Earnings Per Share -$0.40
Diluted Earnings Per Share -$420.6K -$399.7K -$305.7K
COMMON SHARES
Basic Shares Outstanding 34.90M 34.68M 33.68M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.2M $122.8M $153.9M
YoY Change -25.26% -20.23% 37.04%
Cash & Equivalents $110.2M $105.6M $62.47M
Short-Term Investments $0.00 $17.13M $91.40M
Other Short-Term Assets $3.412M $4.662M $3.400M
YoY Change -49.82% 37.12% -2.86%
Inventory $17.85M $16.05M $10.95M
Prepaid Expenses
Receivables $11.83M $10.98M $9.398M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $143.3M $154.5M $177.7M
YoY Change -17.31% -13.08% 34.63%
LONG-TERM ASSETS
Property, Plant & Equipment $7.697M $5.132M $2.824M
YoY Change 170.64% 81.73% 4.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $5.370M $5.711M $2.997M
YoY Change 89.62% 90.56% -16.17%
Total Long-Term Assets $13.30M $11.08M $6.131M
YoY Change 122.17% 80.64% -6.85%
TOTAL ASSETS
Total Short-Term Assets $143.3M $154.5M $177.7M
Total Long-Term Assets $13.30M $11.08M $6.131M
Total Assets $156.6M $165.5M $183.8M
YoY Change -12.65% -9.95% 32.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.379M $4.908M $2.046M
YoY Change -8.43% 139.88% 4.12%
Accrued Expenses $19.80M $16.01M $13.01M
YoY Change 16.78% 23.09% 24.17%
Deferred Revenue $157.0K $448.0K $384.0K
YoY Change -23.79% 16.67% 14.63%
Short-Term Debt $3.905M $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.09M $20.92M $15.05M
YoY Change 33.4% 38.96% 21.0%
LONG-TERM LIABILITIES
Long-Term Debt $44.79M $48.65M $45.16M
YoY Change -7.72% 7.73% 0.84%
Other Long-Term Liabilities $6.513M $7.781M $3.876M
YoY Change 74.8% 100.75% -0.62%
Total Long-Term Liabilities $51.30M $56.43M $49.04M
YoY Change -1.84% 15.08% 0.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.09M $20.92M $15.05M
Total Long-Term Liabilities $51.30M $56.43M $49.04M
Total Liabilities $77.39M $77.35M $64.09M
YoY Change 7.76% 20.69% 4.85%
SHAREHOLDERS EQUITY
Retained Earnings -$288.7M -$274.0M -$222.1M
YoY Change 20.85% 23.35% 21.23%
Common Stock $35.00K $35.00K $34.00K
YoY Change 2.94% 2.94% 9.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $79.24M $88.18M $119.7M
YoY Change
Total Liabilities & Shareholders Equity $156.6M $165.5M $183.8M
YoY Change -12.65% -9.95% 32.66%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$14.69M -$13.89M -$10.32M
YoY Change -12.31% 34.61% 28.82%
Depreciation, Depletion And Amortization $309.0K $241.0K $190.0K
YoY Change 34.35% 26.84% 5.56%
Cash From Operating Activities -$11.43M -$6.495M -$4.420M
YoY Change -19.89% 46.95% -30.39%
INVESTING ACTIVITIES
Capital Expenditures -$2.752M -$1.132M -$110.0K
YoY Change 1000.8% 929.09% -15.38%
Acquisitions
YoY Change
Other Investing Activities $17.00M $9.100M -$7.270M
YoY Change 29.29% -225.17%
Cash From Investing Activities $14.25M $7.968M -$7.380M
YoY Change 10.47% -207.97% 5576.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.771M 2.242M 840.0K
YoY Change -78.84% 166.9% 68.0%
NET CHANGE
Cash From Operating Activities -11.43M -6.495M -4.420M
Cash From Investing Activities 14.25M 7.968M -7.380M
Cash From Financing Activities 1.771M 2.242M 840.0K
Net Change In Cash 4.589M 3.715M -10.96M
YoY Change -34.44% -133.9% 83.28%
FREE CASH FLOW
Cash From Operating Activities -$11.43M -$6.495M -$4.420M
Capital Expenditures -$2.752M -$1.132M -$110.0K
Free Cash Flow -$8.680M -$5.363M -$4.310M
YoY Change -38.09% 24.43% -30.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Central Index Key
EntityCentralIndexKey
0001397702
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38847
dei Entity Registrant Name
EntityRegistrantName
SILK ROAD MEDICAL, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8777622
dei Entity Address Address Line1
EntityAddressAddressLine1
1213 Innsbruck Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunnyvale
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94089
dei City Area Code
CityAreaCode
408
dei Local Phone Number
LocalPhoneNumber
720-9002
dei Entity Address Address Line1
EntityAddressAddressLine1
1213 Innsbruck Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
Sunnyvale
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94089
dei City Area Code
CityAreaCode
408
dei Local Phone Number
LocalPhoneNumber
720-9002
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
SILK
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34896409
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105642000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69466000
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
17127000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
78016000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10976000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9070000
CY2021Q3 us-gaap Inventory Net
InventoryNet
16049000
CY2020Q4 us-gaap Inventory Net
InventoryNet
9989000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4662000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6787000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
154456000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
173328000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5132000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2844000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
232000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5711000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2832000
CY2021Q3 us-gaap Assets
Assets
165531000
CY2020Q4 us-gaap Assets
Assets
179314000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4908000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2598000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16011000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16957000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20919000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19555000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48652000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48533000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7781000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3726000
CY2021Q3 us-gaap Liabilities
Liabilities
77352000
CY2020Q4 us-gaap Liabilities
Liabilities
71814000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
88179000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-10539000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
35000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
362152000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
346318000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
39000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-274009000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238891000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
31916000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
23913000
us-gaap Operating Expenses
OperatingExpenses
88403000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34854822
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34854822
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34249649
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34249649
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
107500000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165531000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
179314000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24701000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20067000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
73210000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
54093000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6076000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5488000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18213000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16074000
CY2021Q3 us-gaap Gross Profit
GrossProfit
18625000
CY2020Q3 us-gaap Gross Profit
GrossProfit
14579000
us-gaap Gross Profit
GrossProfit
54997000
us-gaap Gross Profit
GrossProfit
38019000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6867000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4711000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19611000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11232000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25049000
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19202000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
68792000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
54652000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
3409000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33406000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27865000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13291000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9334000
us-gaap Operating Expenses
OperatingExpenses
65884000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
42000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
249000
us-gaap Investment Income Interest
InvestmentIncomeInterest
183000
us-gaap Investment Income Interest
InvestmentIncomeInterest
951000
CY2021Q3 us-gaap Interest Expense
InterestExpense
633000
CY2020Q3 us-gaap Interest Expense
InterestExpense
1215000
us-gaap Interest Expense
InterestExpense
1884000
us-gaap Interest Expense
InterestExpense
3620000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-74000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13885000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10315000
us-gaap Net Income Loss
NetIncomeLoss
-35118000
us-gaap Net Income Loss
NetIncomeLoss
-30608000
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-2000
CY2020Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-164000
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
-38000
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
150000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-164000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-38000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
150000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13887000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10479000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35156000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30458000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34736015
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33757599
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34536980
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32597007
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
107500000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
848000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
3533000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-10694000
CY2021Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-33000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
101154000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1031000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1086000
us-gaap Inventory Write Down
InventoryWriteDown
109000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1906000
CY2021Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-3000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
96138000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2242000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
3686000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-13885000
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-2000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
88179000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71891000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
274000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1293000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-9941000
CY2020Q1 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
440000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
63957000
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4457000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
70543000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
604000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
801000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
1654000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-10353000
CY2020Q2 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-126000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
127080000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1131000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
2006000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-10315000
CY2020Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
-164000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
119738000
us-gaap Profit Loss
ProfitLoss
-35118000
us-gaap Profit Loss
ProfitLoss
-30608000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
723000
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
563000
us-gaap Share Based Compensation
ShareBasedCompensation
10628000
us-gaap Share Based Compensation
ShareBasedCompensation
4953000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-451000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-145000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
119000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
35000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
627000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
447000
silk Paid In Kind Interest Benefit
PaidInKindInterestBenefit
193000
silk Paid In Kind Interest Benefit
PaidInKindInterestBenefit
249000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-51000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-26000
us-gaap Inventory Write Down
InventoryWriteDown
56000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
771000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3744000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
732000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2014000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
565000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
107000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-200000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1304000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
29000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
629000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2054000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
656000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
176000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27503000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27799000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2006000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
587000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
58884000
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
60400000
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
37180000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
58394000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22291000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
70568000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5207000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2809000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5207000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73377000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36098000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23287000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69776000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39491000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105874000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62778000
us-gaap Interest Paid Net
InterestPaidNet
1571000
us-gaap Interest Paid Net
InterestPaidNet
3336000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1298000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
118000
silk Stock Issuance Costs Incurred But Not Yet Paid
StockIssuanceCostsIncurredButNotYetPaid
25000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3398000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
310000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5569000
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
6808154
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
39.00
us-gaap Use Of Estimates
UseOfEstimates
Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses judgment when making estimates related to provisions for accounts receivable and excess and obsolete inventories, the valuation of deferred tax assets, the reserves for sales returns, and stock-based compensation. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Due to the coronavirus (“COVID-19”) pandemic, there has been continued uncertainty and disruption in the global economy and financial markets. While some of the uncertainties began to lift throughout the first half of 2021, new virus variants, and increased infection rates during this period make the current COVID-related environment highly volatile and uncertain. The Company expect these challenges to continue to impact the number of TCAR procedures in 2021, with procedure volumes impacted by increased COVID-19 hospitalizations and hospital capacity constraints due to the COVID-19 Delta variant. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of September 30, 2021. The Company has also considered information available to it as of the date of issuance of these financial statements and is not aware of any specific events or circumstances that would require an update to its estimates or judgments, or a revision to the carrying value of its assets or liabilities. These estimates may change as new events occur and additional information becomes available. Actual results could differ materially from these estimates.
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
232000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentration of Credit Risk, and Other Risks and Uncertainties The Company is subject to risks related to public health crises such as the global pandemic associated with COVID-19, which has spread to most countries and all 50 states within the United States. The COVID-19 outbreak has negatively impacted, and may continue to negatively impact the Company’s operations, its revenue and overall financial condition by significantly decreasing the number of TCAR procedures performed. The number of TCAR procedures performed, similar to other surgical procedures, has significantly decreased as health care organizations globally prioritized the treatment of patients with COVID-19. In the past governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments, be suspended or canceled to focus limited resources and personnel and hospital capacity toward the treatment of COVID-19 and to avoid exposing patients to COVID-19. These measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will continue to negatively impact the Company’s revenue while the pandemic continues. New virus variants, and increased infection rates continue to make the current COVID-related environment highly volatile and uncertain. Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, investments and accounts receivable to the extent of the amounts recorded on the balance sheet. Cash, cash equivalents, and investments are deposited in financial institutions which, at times, may be in excess of federally insured limits. Cash equivalents are invested in highly rated money market funds and United States treasury bills. The Company invests in a variety of financial instruments, such as, but not limited to, commercial paper, corporate bonds/notes, United States Government securities, asset-backed securities and, by policy, limits the amount of credit exposure with any one financial institution or commercial issuer. The Company has not experienced any material losses on its deposits of cash and cash equivalents or investments during the three and nine months ended September 30, 2021 and 2020. The Company’s accounts receivable are due from a variety of health care organizations in the United States. At September 30, 2021 and December 31, 2020, no customer represented 10% or more of the Company’s accounts receivable. For the three and nine months ended September 30, 2021 and 2020, there were no customers that represented 10% or more of revenue. The Company provides for uncollectible amounts when specific credit problems are identified. In doing so, the Company analyzes historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for expected credit losses on customer accounts. The Company manufactures certain of its commercial products in-house. Certain of the Company’s product components and sub-assemblies continue to be manufactured by sole suppliers, the most significant of which is the ENROUTE Transcarotid Stent System, manufactured by Cordis Corporation, or Cordis. Disruption in component or sub-assembly supply from these manufacturers or from in-house production would have a negative impact on the Company’s financial position and results of operations. The Company is subject to certain risks, including that its devices may not be approved or cleared for marketing by governmental authorities or be successfully marketed. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence upon government and third-party payers to provide adequate coverage and reimbursement, dependence on key personnel and suppliers, protection of proprietary technology, product liability claims, and compliance with government regulations. Existing or future devices developed by the Company may require approvals or clearances from the FDA or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If the Company were denied or delayed in receiving such approvals or clearances, it may be necessary to adjust operations to align with the Company’s currently approved portfolio. If clearance for the products in the current portfolio were withdrawn by the FDA, this would have a material adverse impact on the Company.
CY2021Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
164000
CY2020Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
71000
CY2021Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-13885000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10315000
us-gaap Net Income Loss
NetIncomeLoss
-35118000
us-gaap Net Income Loss
NetIncomeLoss
-30608000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34736015
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33757599
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34536980
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32597007
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4280389
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4495877
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2021Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2520000
CY2021Q3 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P41D
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
15497000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3000
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
2195000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1785000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
13876000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10599000
CY2021Q3 us-gaap Inventory Gross
InventoryGross
16071000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
12384000
CY2021Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
23000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2395000
CY2021Q3 us-gaap Inventory Net
InventoryNet
16049000
CY2020Q4 us-gaap Inventory Net
InventoryNet
9989000
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0
CY2021Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
10228000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
9573000
CY2021Q3 silk Provisions For Sales Returns
ProvisionsForSalesReturns
410000
CY2020Q4 silk Provisions For Sales Returns
ProvisionsForSalesReturns
820000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1909000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1003000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
850000
CY2021Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
608000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
518000
CY2021Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
15000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1696000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
448000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
206000
CY2021Q3 silk Accrued Travel Expenses Current
AccruedTravelExpensesCurrent
552000
CY2020Q4 silk Accrued Travel Expenses Current
AccruedTravelExpensesCurrent
237000
CY2021Q3 silk Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
150000
CY2020Q4 silk Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
113000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
688000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
424000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16011000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
16957000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
588000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6257000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
25749000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
21457000
CY2021Q3 silk Long Term Debt Gross Before Accretion Of Closing Fees
LongTermDebtGrossBeforeAccretionOfClosingFees
54051000
CY2021Q3 silk Long Term Debt Unpaid Interest
LongTermDebtUnpaidInterest
5051000
CY2021Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
348000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
48652000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
3398000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3398000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
369000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
217000
us-gaap Operating Lease Cost
OperatingLeaseCost
875000
us-gaap Operating Lease Cost
OperatingLeaseCost
652000
CY2021Q3 silk Operating Lease Cash Paid
OperatingLeaseCashPaid
-1043000
CY2020Q3 silk Operating Lease Cash Paid
OperatingLeaseCashPaid
197000
silk Operating Lease Cash Paid
OperatingLeaseCashPaid
-650000
silk Operating Lease Cash Paid
OperatingLeaseCashPaid
569000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y1M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
37.61
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2798000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1003000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.46
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
850000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6574000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2850000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7577000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3700000
CY2021Q3 silk Lessee Operating Lease Liability To Be Paid Year One Net
LesseeOperatingLeaseLiabilityToBePaidYearOneNet
-300000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1576000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1970000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1767000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
886000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
3686000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
9585000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2008000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7577000
CY2021Q3 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
11471000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34854822
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34854822
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4237828
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.56
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M17D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
197407000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
323057
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
53.94
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
548699
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
82046
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3930140
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M19D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
137958000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2660361
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.41
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M10D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
113810000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3930140
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
20.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y11M19D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
137958000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3686000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2006000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10628000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4953000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
19994000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.90
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2021Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
308000
CY2020Q3 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
195000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1003000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
717000

Files In Submission

Name View Source Status
0001397702-21-000063-index-headers.html Edgar Link pending
0001397702-21-000063-index.html Edgar Link pending
0001397702-21-000063.txt Edgar Link pending
0001397702-21-000063-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
silk-20210930.xsd Edgar Link pending
silk-20210930x10q.htm Edgar Link pending
silk-20210930x10q_htm.xml Edgar Link completed
silk-20210930xex31_1.htm Edgar Link pending
silk-20210930xex31_2.htm Edgar Link pending
silk-20210930xex32_1.htm Edgar Link pending
silk-20210930_cal.xml Edgar Link unprocessable
silk-20210930_def.xml Edgar Link unprocessable
silk-20210930_lab.xml Edgar Link unprocessable
silk-20210930_pre.xml Edgar Link unprocessable